1887

Journal of Medical Microbiology logo

Volume 70, Issue 12

Antifungal susceptibility profile of invasive isolates (2009–2020) from a tertiary care hospital laboratory in Pakistan No Access

Abstract

Invasive infections with are a global concern due to poor clinical outcomes and propensity to acquire resistance to antifungal agents

Monitoring emerging resistance and trends in , an important agent of candidemia in Pakistan, is critical for patient management; data that is missing from Pakistan

Thus, this study evaluated antifungal resistance and MICs) distribution in invasive isolates from Pakistan

This cross-sectional and retrospective study was conducted from January 2009 to March 2020 at a clinical laboratory in Pakistan that has a nation-wide network. Antifungal susceptibility data of 277 candidemia, deep organ and soft tissue (invasive) isolates against fluconazole, itraconazole, voriconazole, posaconazole, anidulafungin, micafungin, caspofungin and amphotericin B was retrieved. Susceptibility testing was performed using colorimetric broth microdilution and interpreted using CLSI criteria. Demographics, clinical history and outcome were studied. Chi-square test was used to demonstrate association between antifungal resistance and clinical characteristics of the patients

We identified 277 patients with invasive infection. Of which 48 (18.4%) isolates were resistant to fluconazole (MIC ≥64 mg l), one isolate each was resistant to amphotericin (MIC=2 mg l), anidulafungin (MIC=1 mg l) and micafungin (MIC=0.5 mg l). MIC for fluconazole was 64 mg l and other triazoles 2 mg l, caspofungin 0.12 mg l, anidulafungin 0.06 mg l, micafungin 0.03 mg l and amphotericin 0.5 mg l. Fluconazole MIC ≥64 mg l, caspofungin MIC >0.06 mg l and amphotericin MIC >0.25 mg l (above MIC) were significantly associated with patient being alive at the time of reporting, no use of healthcare devices, nor infection with other fungi. Fluconazole resistance was significantly associated with prior antifungal use by the patient

Surveillance data of antifungal resistance among common species should be monitored closely for identification of resistant strains.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): antifungal resistance , Candida glabrata , invasive infections , minimum inhibitory concentrations and Pakistan
Funding
This study was supported by the:
  • University Research Council, Aga Khan University
    • Principle Award Recipient: SabaMemon
© 2021 The Authors
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001459
2021-12-08
2024-05-14
Loading full text...

Full text loading...

References

  1. Makanjuola O, Bongomin F, Fayemiwo SA. An update on the roles of non-albicans candida species in vulvovaginitis. JoF 2018; 4:121 [View Article]
     [Google Scholar]
  2. Taei M, Chadeganipour M, Mohammadi R. An alarming rise of non-albicans Candida species and uncommon yeasts in the clinical samples; a combination of various molecular techniques for identification of etiologic agents. BMC Res Notes 2019; 12:779 [View Article]
     [Google Scholar]
  3. Gupta A, Gupta A, Varma A. Candida glabrata candidemia: An emerging threat in critically ill patients. Indian J Crit Care Med 2015; 19:151–154 [View Article] [PubMed]
     [Google Scholar]
  4. Byun SA, Won EJ, Kim M-N, Lee WG, Lee K et al. Multilocus sequence typing (MLST) genotypes of Candida glabrata bloodstream isolates in Korea: Association with antifungal resistance, mutations in mismatch repair gene (Msh2), and clinical outcomes. Front Microbiol 2018; 9:1–10 [View Article]
     [Google Scholar]
  5. Sampaio P, Pais C. Epidemiology of Invasive Candidiasis and Challenges for the Mycology Laboratory: Specificities of Candida glabrata. Curr Clin Micro Rpt 2014; 1:1–9 [View Article]
     [Google Scholar]
  6. Al-Baqsami ZF, Ahmad S, Khan Z. Antifungal drug susceptibility, molecular basis of resistance to echinocandins and molecular epidemiology of fluconazole resistance among clinical Candida glabrata isolates in Kuwait. Sci Rep 2020; 10:5–7 [View Article]
     [Google Scholar]
  7. Mota S, Alves R, Carneiro C, Silva S, Brown AJ et al. Candida glabrata susceptibility to antifungals and phagocytosis is modulated by acetate. Front Microbiol 2015; 6:1–12 [View Article]
     [Google Scholar]
  8. Kumar K, Askari F, Sahu MS, Kaur R. Candida glabrata: A lot more than meets the eye. Microorganisms 2019; 7:39 [View Article]
     [Google Scholar]
  9. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA et al. Executive summary: Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of America. Clin Infect Dis 2016; 62:409–417 [View Article]
     [Google Scholar]
  10. Rivero-Menendez O, Navarro-Rodriguez P, Bernal-Martinez L, Martin-Cano G, Lopez-Perez L et al. Clinical and laboratory development of echinocandin resistance in Candida glabrata: Molecular characterization. Front Microbiol 2019; 10:1–12 [View Article]
     [Google Scholar]
  11. Perlin DS. Echinocandin resistance in Candida. Clin Infect Dis 2015; 61:S612–S617 [View Article]
     [Google Scholar]
  12. Tan TY, Hsu LY, Alejandria MM, Chaiwarith R, Chinniah T et al. Antifungal susceptibility of invasive Candida bloodstream isolates from the Asia-Pacific region. Med Mycol 2016; 54:471–477 [View Article] [PubMed]
     [Google Scholar]
  13. Pandey N, Gupta MK, Paul P, Tilak R. Necessity to identify candida species accurately with minimum inhibitory concentration determination in each case of bloodstream infections. J Infect Public Health 2020; 13:753–758 [View Article] [PubMed]
     [Google Scholar]
  14. Farooqi JQ, Jabeen K, Saeed N, Iqbal N, Malik B et al. vasive candidiasis in Pakistan: Clinical characteristics, species distribution and antifungal susceptibility. J Med Microbiol 2013; 62:259–268 [View Article] [PubMed]
     [Google Scholar]
  15. Tasneem U, Siddiqui MT, Faryal R, Shah AA. Prevalence and antifungal susceptibility of Candida species in a tertiary care hospital in Islamabad, Pakistan. J Pak Med Assoc 2017; 67:986–991 [PubMed]
     [Google Scholar]
  16. Clinical and Laboratory Standards Institute (CLSI) Reference method for broth dilution. Ref method broth dilution Antifung susceptibility Test yeasts Approv Stand 3th ed 20080–13
     [Google Scholar]
  17. Pfaller MA, Andes DR, Diekema DJ, Horn DL, Reboli AC et al. Epidemiology and outcomes of invasive candidiasis due to non-albicans species of Candida in 2,496 patients: Data from the Prospective Antifungal Therapy (PATH) registry 2004-2008. PLoS One 2014; 9:e101510 [View Article] [PubMed]
     [Google Scholar]
  18. Yao D, Chen J, Chen W, Li Z, Hu X. Mechanisms of azole resistance in clinical isolates of Candida glabrata from two hospitals in China. Infect Drug Resist 2019; 12:771–781 [View Article] [PubMed]
     [Google Scholar]
  19. Pfaller MA, Diekema DJ, Turnidge JD, Castanheira M, Jones RN. Twenty years of the SENTRY antifungal surveillance program: Results for Candida species from 1997-2016. Open Forum Infect Dis 2019; 6:S79–S94 [View Article] [PubMed]
     [Google Scholar]
  20. Hussain AS, Ahmed AM, Arbab S, Ariff S, Ali R et al. CLABSI reduction using evidence based interventions and nurse empowerment: A quality improvement initiative from a tertiary care NICU in Pakistan. Arch Dis Child 2021; 106:394–400 [View Article] [PubMed]
     [Google Scholar]
  21. Borman AM, Muller J, Walsh-Quantick J, Szekely A, Patterson Z et al. MIC distributions for amphotericin B, fluconazole, itraconazole, voriconazole, flucytosine and anidulafungin and 35 uncommon pathogenic yeast species from the UK determined using the CLSI broth microdilution method. J Antimicrob Chemother 2020; 75:1194–1205 [View Article] [PubMed]
     [Google Scholar]
  22. Whaley SG, Berkow EL, Rybak JM, Nishimoto AT, Barker KS et al. Azole antifungal resistance in Candida albicans and emerging non-albicans Candida Species. Front Microbiol 2017; 7:1–12 [View Article]
     [Google Scholar]
  23. Aitken M, Kleinrock M. Global medicines use in 2020 outlook and implications. IQVIA Inst Hum Data Sci 20151–43
     [Google Scholar]
  24. Bhattacharya S, Sae-Tia S, Fries BC. Candidiasis and mechanisms of antifungal resistance. Antibiotics 2020; 9:312 [View Article]
     [Google Scholar]
  25. Krogh-Madsen M, Arendrup MC, Heslet L, Knudsen JD. Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically Ill patient. Clin Infect Dis 2006; 42:938–944 [View Article] [PubMed]
     [Google Scholar]
  26. Farooqi J, Jabeen K, Saeed N, Zafar A, Brandt ME et al. Species identification of invasive yeasts including Candida in Pakistan: Limitations of phenotypic methods. J Pak Med Assoc 2012; 62:995–998 [PubMed]
     [Google Scholar]
  27. Pfaller MA, Andes DR, Diekema DJ, Horn DL, Reboli AC et al. No title epidemiology and outcomes of invasive candidiasis due to non-albicans species of Candida in 2,496 patients: Data from the Prospective Antifungal Therapy (PATH) registry 2004–2008. PLoS One 2014; 9:e101510 [View Article]
     [Google Scholar]
  28. Lamoth F, Lockhart SR, Berkow EL, Calandra T. Changes in the epidemiological landscape of invasive candidiasis. J Antimicrob Chemother 2018; 73:i4–i13 [View Article] [PubMed]
     [Google Scholar]
  29. Lindberg E, Hammarström H, Ataollahy N, Kondori N. Species distribution and antifungal drug susceptibilities of yeasts isolated from the blood samples of patients with candidemia. Sci Rep 2019; 9:12–17 [View Article]
     [Google Scholar]
  30. Henry-Stanley MJ, Garni RM, Alice Johnson M, Bendel CM, Wells CL. Comparative abilities of Candida glabrata and Candida albicans to colonize and translocate from the intestinal tract of antibiotic-treated mice. Microbial Ecology in Health and Disease 2009; 17:129–137 [View Article]
     [Google Scholar]
  31. Arendrup MC, Patterson TF. Multidrug-resistant candida: Epidemiology, molecular mechanisms, and treatment. J Infect Dis 2017; 216:S445–S451 [View Article] [PubMed]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.001459
Loading
Antifungal susceptibility profile of invasive Candida glabrata isolates (2009–2020) from a tertiary care hospital laboratory in Pakistan
J. Med. Microbiol. 70, 001459 (2021); https://doi.org/10.1099/jmm.0.001459
/content/journal/jmm/10.1099/jmm.0.001459
/content/journal/jmm/10.1099/jmm.0.001459
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error